Bio-Connect

Anti-Amyloid beta A4 protein [LY2062430 (Solanezumab, hu266)]

AB04185-23.0
Absolute Antibody
ApplicationsELISA
Product group Antibodies
ReactivityHuman
TargetAPP
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Absolute Antibody
  • Product Name
    Anti-Amyloid beta A4 protein [LY2062430 (Solanezumab, hu266)]
  • Delivery Days Customer
    9
  • Application Supplier Note
    The human IgG1 version of this antibody binds amyloid beta peptide Abeta1-42 with a binding affinity of Kd= 4pM in an in vitro BIAcore assay. The binding characterization of this antibody towards Abeta1-42-BSA conjugate was done using ELISA (US8591894). A study in patients with Alzheimers disease (AD) suggested that a single dose of solanezumab was generally well tolerated, except that mild self-limited symptoms consistent with infusion reactions occurred in few patients when higher doses are given. A dose-dependent change in plasma and CSF Abeta was also observed (PMID: 20375655). The original mouse antibody 266 slowed Abeta accumulation in the brain but failed to deplete Abeta plaques in animal studies (PMID: 11438712). This humanized antibody is likely to have impeded the efflux of soluble Abeta from the brain in patients owing to the formation of Abeta-antibody complexes in the brain interstitial fluid and cerebrospinal fluid, as suggested from animal studies (PMID: 24638135). Phase 1 and 2 studies of solanezumab revealed evidence of target engagement by dose-dependent increases in plasma and CSF total Abeta (PMID: 20375655; 22672770). In the phase 2 study of mild to moderate AD, 12 weeks of solanezumab treatment yielded a dose-dependent increase in CSF-free Abeta42, suggesting a shift in equilibria sufficient to mobilize Abeta42 from plaques (PMID: 22672770). In the first phase III studies, solanezumab did not demonstrate significant benefit for the primary outcomes in either study but showed a favorable safety profile (PMID: 26238576).
  • Applications
    ELISA
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    LY2062430 (Solanezumab, hu266)
  • Gene ID351
  • Target name
    APP
  • Target description
    amyloid beta precursor protein
  • Target synonyms
    AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, alpha-sAPP, preA4, amyloid-beta precursor protein, alzheimer disease amyloid A4 protein homolog, alzheimer disease amyloid protein, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid precursor protein, beta-amyloid peptide, beta-amyloid peptide(1-40), beta-amyloid peptide(1-42), beta-amyloid precursor protein, cerebral vascular amyloid peptide, peptidase nexin-II, protease nexin-II, testicular tissue protein Li 2
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDP05067
  • Protein Name
    Amyloid-beta precursor protein
  • Scientific Description
    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
  • Reactivity
    Human
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    41116161